- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3- How Payers Will Access the Value of New Agents
Dr Weber said that despite all of the newer agents in development, the NCCN still offers comprehensive guidelines for the treatment of melanoma.
Dr Weber said that despite all of the newer agents in development, the NCCN still offers comprehensive guidelines for the treatment of melanoma.
“There’s so much innovation and so many exciting new therapies that there aren’t hard data on how to sequence them, and so you really have to rely on experts to provide that kind of guidance to people out there in the community treating patients,” said Dr Malin.
Dr Malin also noted her concerns with the costs of newer agents. She explained that the majority of small independent practices will be concerned about prescribing expensive medications when they do not know what the patient’s insurance will cover, or if the patient can pay their copay.
Subjective and Objective Impacts of Ambulatory AI Scribes
January 8th 2026Although the vast majority of physicians using an artificial intelligence (AI) scribe perceived a reduction in documentation time, those with the most actual time savings had higher relative baseline levels of documentation time.
Read More
